Doing Life Sciences Deals in 2024 - Licensing, M&A, and More
hosted by the Life Sciences Sector and the Boston Chapter

Thursday, April 11, 2024

2:00 pm - 7:00 pm
at
Mintz
One Financial Center
Boston, MA 02111

Drinks & Appetizers will be served

Program:
Panels include Structuring Your Life Sciences Transaction - Licensing vs. M&A vs. Asset Sale and Key Issues for Your Biopharma Licensing Deal - IP, Scientific, and More

Learning Outcomes:

• Deal trends
• Considerations when structuring your deal
• Should you do an M&A vs. license vs. asset sale – considerations for deal
• Strategies for doing a deal with big pharma
• What does big pharma look for in a deal structure?
• Is licensing a way to an M&A deal with big pharma?
• Key non-economic issues for your biopharma licensing deal
• IP – how does big pharma diligence it, and how can a biotech satisfy a big pharma
• Scientific rigor – How does a big pharma evaluate your science?
• How do these key issues play into your license agreement?
• How do you run an efficient and productive diligence process?
• How should you time your licensing deal with your data readout?

CLICK HERE FOR AGENDA

Speakers:

	Panel 1 - 2:30-3:30 - Structuring Your Life Sciences Transaction: Licensing vs. M&A vs. Asset Sale
	Jeff Caravella, Business Development, Interventional Oncology, Johnson & Johnson
	Andy Meyerson, Managing Director, Locust Walk
	Veronica Miller, Executive Director, Business Development, Astria Therapeutics, Inc.
	Jonathan Kiburz, Vice President, Business Development Transactions, GSK
	Moderator: Cheryl Reicin, International Chair, Life Sciences, Mintz
	Panel 2 - 3:45-4:45 - Key Issues for Your Biopharma Licensing Deal - IP, Scientific Diligence, and More
	Fanny Cavalie, Chief Strategy and Business Operations Officer, Foghorn Therapeutics
	Beatriz Gadala-Maria, Senior Director, Transactions, Business Development, Early Stage Oncology Transactions, AstraZeneca
	Imran Nasrullah, Vice President & Head, Collaborate2Cure Hub, US, Business Development & Licensing, Bayer Pharmaceuticals
	Moderator: Adam Falconi, Attorney, Mintz

Thank you to our host & sponsor:

Email Consent:  By registering for this event, you permit LES to use your email address to communicate with you regarding LES events and their other services. You will have the ability to unsubscribe from these communications going forward.